BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 2594602)

  • 1. Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy.
    McIntyre HD; Cameron DP; Urquhart SM; Davies WE
    Postgrad Med J; 1989 Apr; 65(762):244-6. PubMed ID: 2594602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate.
    Gallacher SJ; Ralston SH; Dryburgh FJ; Logue FC; Allam BF; Boyce BF; Boyle IT
    Postgrad Med J; 1990 Nov; 66(781):918-22. PubMed ID: 2267202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminohydroxypropylidene bisphosphonate (AHPrBP) treatment of severe immobilization hypercalcaemia in a young patient.
    Varache N; Audran M; Clochon P; Lortholary A; Bouachour G; Alquier P; Basle MF
    Clin Rheumatol; 1991 Sep; 10(3):328-32. PubMed ID: 1790647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia.
    Dodwell DJ; Howell A; Morton AR; Daley-Yates PT; Hoggarth CR
    Postgrad Med J; 1992 Jun; 68(800):434-9. PubMed ID: 1437922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy.
    Wimalawansa SJ
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):591-5. PubMed ID: 7828347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immobilization hypercalcemia in incomplete paraplegia: successful treatment with pamidronate.
    Kedlaya D; Brandstater ME; Lee JK
    Arch Phys Med Rehabil; 1998 Feb; 79(2):222-5. PubMed ID: 9474008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An audit of the management of malignant hypercalcaemia.
    Gerrard GE; Dodwell DJ; Vail A; Watters J; Overend MA
    Clin Oncol (R Coll Radiol); 1996; 8(1):39-42. PubMed ID: 8688360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hypercalcaemia in thyrotoxicosis with aminohydroxypropylidene diphosphonate.
    Tan TT; Alzaid AA; Sutcliffe N; Gardner MD; Thomson JA; Boyle IT
    Postgrad Med J; 1988 Mar; 64(749):224-7. PubMed ID: 3174541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
    Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
    Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term control of hypercalcaemia in an infant with williams-Beuren syndrome after a single infusion of biphosphonate (Pamidronate).
    Oliveri B; Mastaglia SR; Mautalen C; Gravano JC; Pardo Argerich L
    Acta Paediatr; 2004 Jul; 93(7):1002-3. PubMed ID: 15303821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.
    Gurney H; Kefford R; Stuart-Harris R
    Lancet; 1989 Jul; 2(8657):241-4. PubMed ID: 2569054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
    Ralston SH; Alzaid AA; Gardner MD; Boyle IT
    Br Med J (Clin Res Ed); 1986 Jun; 292(6535):1549-50. PubMed ID: 3087513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
    Body JJ; Dumon JC
    Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D intoxication and hypercalcaemia in an infant treated with pamidronate infusions.
    Ezgu FS; Buyan N; Gündüz M; Tümer L; Okur I; Hasanoglu A
    Eur J Pediatr; 2004 Mar; 163(3):163-5. PubMed ID: 14714183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
    Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
    Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.
    Tal A; Graves L
    South Med J; 1996 Jun; 89(6):637-40. PubMed ID: 8638211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates for treatment of childhood hypercalcemia.
    Lteif AN; Zimmerman D
    Pediatrics; 1998 Oct; 102(4 Pt 1):990-3. PubMed ID: 9755274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pamidronate in the treatment of tumor-associated hypercalcemia].
    Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
    Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
    Fraser WD; Logue FC; Gallacher SJ; O'Reilly DS; Beastall GH; Ralston SH; Boyle IT
    Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous pamidronate sodium therapy in immobilization-related hypercalcemia.
    Tamion F; Bonmarchand F; Girault C; Chevron V; Leroy J
    Clin Nephrol; 1995 Feb; 43(2):138-9. PubMed ID: 7736680
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.